These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 11735651)

  • 1. Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions.
    Gex-Fabry M; Balant-Gorgia AE; Balant LP
    Drug Saf; 2001; 24(13):947-59. PubMed ID: 11735651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions: evaluation of a paired approach for psychotropic medication.
    Gex-Fabry M; Balant-Gorgia AE; Balant LP
    Ther Drug Monit; 1997 Feb; 19(1):1-10. PubMed ID: 9029739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects].
    Marquet P
    Acta Clin Belg; 1999; 53 Suppl 1():2-12. PubMed ID: 10216973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
    Johannessen SI; Tomson T
    Clin Pharmacokinet; 2006; 45(11):1061-75. PubMed ID: 17048972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a role for therapeutic drug monitoring of new anticonvulsants?
    Perucca E
    Clin Pharmacokinet; 2000 Mar; 38(3):191-204. PubMed ID: 10749516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication.
    Gex-Fabry M; Balant-Gorgia AE; Balant LP
    Ther Drug Monit; 2003 Feb; 25(1):46-53. PubMed ID: 12548144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry.
    Hiemke C
    Eur J Clin Pharmacol; 2008 Feb; 64(2):159-66. PubMed ID: 18196227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring of ziprasidone in a clinical treatment setting.
    Chermá MD; Reis M; Hägg S; Ahlner J; Bengtsson F
    Ther Drug Monit; 2008 Dec; 30(6):682-8. PubMed ID: 18824954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.
    Spina E; Hiemke C; de Leon J
    Expert Opin Drug Metab Toxicol; 2016; 12(4):407-22. PubMed ID: 26878495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
    Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
    J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
    Johannessen Landmark C; Baftiu A; Tysse I; Valsø B; Larsson PG; Rytter E; Johannessen SI
    Ther Drug Monit; 2012 Aug; 34(4):440-5. PubMed ID: 22777154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic principles of immunosuppressive drugs.
    Budde K; Glander P
    Ann Transplant; 2008; 13(3):5-10. PubMed ID: 18806727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring in the treatment of tuberculosis.
    Peloquin CA
    Drugs; 2002; 62(15):2169-83. PubMed ID: 12381217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome.
    Svendsen T; Brodtkorb E; Reimers A; Molden E; Sætre E; Johannessen SI; Johannessen Landmark C
    Epilepsy Res; 2017 Jan; 129():125-131. PubMed ID: 28043062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.
    Baumann P; Hiemke C; Ulrich S; Eckermann G; Gaertner I; Gerlach M; Kuss HJ; Laux G; Müller-Oerlinghausen B; Rao ML; Riederer P; Zernig G;
    Pharmacopsychiatry; 2004 Nov; 37(6):243-65. PubMed ID: 15551191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.